P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027

P1/2, N=188, Recruiting, Novartis Pharmaceuticals

The combination of ARV-110 and ponatinib exerted a significant inhibitory and synergistic effect on CRPC cells. Additionally, the substantial accumulation of reactive oxygen species induced by the combination strategy was related to the joint downregulation of catalase by the two drugs through different mechanisms. In conclusion, this study described a new strategy for the treatment of CRPC and clarified the molecular mechanisms of the combination strategy, providing a new theoretical basis for the precision treatment of CRPC.

P2, N=134, Active, not recruiting, Novartis Pharmaceuticals

This mapping identified 755 new non-functional AR variants and revealed 225 and 40 new variants resistant to enzalutamide and bavdegalutamide, an AR degrader, respectively. Our findings also enabled prognosis prediction for patients with prostate cancer based on AR mutation profiles. The broader implications of the study include improved androgen insensitivity syndrome diagnosis, better prostate cancer prognosis prediction and precision treatments for patients with prostate cancer.

P2, N=130, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P1/2, N=52, Not yet recruiting, AstraZeneca AB

Functional studies reveal that AR-driven autophagy confers resistance to BRAFi by enhancing cellular survival under therapeutic stress. Our findings establish AR-regulated autophagy as a critical resistance mechanism and provide preclinical evidence for combining AR-targeting PROTAC degrader ARV110 with autophagy inhibitors to overcome BRAFi resistance.

P1, N=65, Not yet recruiting, Gan & Lee Pharmaceuticals.

P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting

P1/2, N=46, Recruiting, Novartis Pharma AG

P1/2, N=76, Not yet recruiting, Novartis Pharma AG